Sansure Biotech

Sansure Biotech Inc. is a provider of integrated in vitro diagnostic solutions centered on self-innovative gene technology, encompassing diagnostic reagents, instruments, and third-party medical testing services. Listed on the STAR Market (stock code: 688289), it ranks among the top 100 global medical device enterprises and appears on the list of China's top 100 pharmaceutical industrial enterprises. The company aims to be a universal provider of gene technology, supporting China’s precision medicine system and tiered medical treatment framework. It serves as a national demonstration center for gene detection technology applications, a national-local joint engineering research center for infectious disease and tumor gene diagnostics, a national enterprise technology center, a national technological innovation demonstration enterprise, a national postdoctoral research workstation, and a national intellectual property demonstration enterprise. As a leading enterprise in China’s molecular diagnostics sector, Sansure is accelerating its transformation into an internationally leading in vitro diagnostics company and advancing toward becoming a world-class enterprise. Headquartered in Changsha, the company has established three major industrial bases in Changsha, Shanghai, and Beijing, with subsidiaries or branches in key cities across China such as Chengdu, and in significant global regions including the United States, the United Kingdom, France, Indonesia, the Philippines, and Thailand. Guided by its mission to provide affordable and high-quality gene technology, products, and services to people worldwide, the company focuses on promoting the "five modernizations" of gene technology: high precision, simplification, systematization, mobility, and intelligence. It has independently developed core technologies such as high-precision "magnetic bead method," rapid and convenient "one-step method," versatile "fully automatic unified sample processing," and "POCT mobile molecular diagnostics." Additionally, it has built technical platforms covering real-time fluorescent PCR, multiplex PCR, gene chips, gene sequencing, mobile molecular diagnostics, nucleic acid mass spectrometry, immunoassays, and bioinformatics. The company has received nearly 60 national-level major awards, including the National Science and Technology Progress Award (second class) and the China Patent Award, while undertaking over 50 national and provincial major projects, including those under China’s 12th and 13th Five-Year Plans. Gradually, it has constructed a new ecosystem for universal and all-scenario gene technology applications, driving domestic industry standards to surpass international advanced levels, effectively breaking import monopolies, and propelling life science technologies from disease solutions to intelligent health management, from tertiary hospitals to grassroots medical institutions, and from B-end to C-end in comprehensive upgrades. This transformation achieves coverage across all demographics, all medical institutions, and all channels. The company is committed to creating premium projects, developing more than 1,000 products that outperform both domestic and international advanced levels in areas such as infectious disease prevention and control, maternal and child health, blood safety, cancer prevention and control, companion diagnostics, and agricultural biotechnology. It offers over 2,200 types of testing services, forming an all-in-one industrial chain solution that integrates reagents, instruments, sequencing services, third-party medical testing services, and molecular laboratory co-construction. Its products and solutions serve more than 160 countries and regions globally, providing testing products for over 3 billion people cumulatively.